Research ExplorerPublicationsEfficacy of Favipiravir Alone and in Combination With Ribavi...

Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever

Standard

Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. / Oestereich, Lisa; Rieger, Toni; Lüdtke, Anja; Ruibal, Paula; Wurr, Stephanie; Pallasch, Elisa; Bockholt, Sabrina; Krasemann, Susanne; Muñoz-Fontela, César; Günther, Stephan.

In: J INFECT DIS, Vol. 213, No. 6, 03.2016, p. 934-948.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Oestereich, L, Rieger, T, Lüdtke, A, Ruibal, P, Wurr, S, Pallasch, E, Bockholt, S, Krasemann, S, Muñoz-Fontela, C & Günther, S 2016, 'Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever', J INFECT DIS, vol. 213, no. 6, pp. 934-948. https://doi.org/10.1093/infdis/jiv522

APA

Oestereich, L., Rieger, T., Lüdtke, A., Ruibal, P., Wurr, S., Pallasch, E., Bockholt, S., Krasemann, S., Muñoz-Fontela, C., & Günther, S. (2016). Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J INFECT DIS, 213(6), 934-948. https://doi.org/10.1093/infdis/jiv522

Vancouver

Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E et al. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J INFECT DIS. 2016 Mar;213(6):934-948. https://doi.org/10.1093/infdis/jiv522

Bibtex

@article{a9fbffb3cc484655a1155e88031c6422,
title = "Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever",
abstract = "We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin. Favipiravir suppressed Lassa virus replication in cell culture by 5 log10 units. In a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalized levels of cell-damage markers. Treatment with 300 mg/kg per day, commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, rescued 100% of Lassa virus-infected mice. We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased survival rate and extended survival time when combining suboptimal doses in vivo.",
author = "Lisa Oestereich and Toni Rieger and Anja L{\"u}dtke and Paula Ruibal and Stephanie Wurr and Elisa Pallasch and Sabrina Bockholt and Susanne Krasemann and C{\'e}sar Mu{\~n}oz-Fontela and Stephan G{\"u}nther",
note = "{\textcopyright} The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.",
year = "2016",
month = mar,
doi = "10.1093/infdis/jiv522",
language = "English",
volume = "213",
pages = "934--948",
journal = "J INFECT DIS",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever

AU - Oestereich, Lisa

AU - Rieger, Toni

AU - Lüdtke, Anja

AU - Ruibal, Paula

AU - Wurr, Stephanie

AU - Pallasch, Elisa

AU - Bockholt, Sabrina

AU - Krasemann, Susanne

AU - Muñoz-Fontela, César

AU - Günther, Stephan

N1 - © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2016/3

Y1 - 2016/3

N2 - We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin. Favipiravir suppressed Lassa virus replication in cell culture by 5 log10 units. In a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalized levels of cell-damage markers. Treatment with 300 mg/kg per day, commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, rescued 100% of Lassa virus-infected mice. We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased survival rate and extended survival time when combining suboptimal doses in vivo.

AB - We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin. Favipiravir suppressed Lassa virus replication in cell culture by 5 log10 units. In a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalized levels of cell-damage markers. Treatment with 300 mg/kg per day, commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, rescued 100% of Lassa virus-infected mice. We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased survival rate and extended survival time when combining suboptimal doses in vivo.

U2 - 10.1093/infdis/jiv522

DO - 10.1093/infdis/jiv522

M3 - SCORING: Journal article

C2 - 26531247

VL - 213

SP - 934

EP - 948

JO - J INFECT DIS

JF - J INFECT DIS

SN - 0022-1899

IS - 6

ER -